fat-话题@MedSci - 梅斯（MedSci）

#fat#

32篇内容 | 1600人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2029971, encodeId=869d20299e162, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=J Clin Oncol：Afatinib（阿法替尼）联合Pembrolizumab（帕博利珠单抗）治疗复发或转移性头颈鳞状细胞癌（HNSCC）患者的疗效：ALPHA研究, objectType=article, longId=294454, objectId=3f302944546a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f302944546a, replyNumber=0, likeNumber=92, createdTime=2022-06-21, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f302944546a, moduleTitle=J Clin Oncol：Afatinib（阿法替尼）联合Pembrolizumab（帕博利珠单抗）治疗复发或转移性头颈鳞状细胞癌（HNSCC）患者的疗效：ALPHA研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3f302944546a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029968, encodeId=f9752029968e7, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=Front Oncol：Afatinib（阿法替尼）治疗EGFR突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）的疗效：来自3个IIIb期研究的合并分析, objectType=article, longId=220865, objectId=1061220865c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1061220865c1, replyNumber=0, likeNumber=74, createdTime=2022-05-08, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1061220865c1, moduleTitle=Front Oncol：Afatinib（阿法替尼）治疗EGFR突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）的疗效：来自3个IIIb期研究的合并分析, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1061220865c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029969, encodeId=ccea2029969bf, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=A high serum-free fatty acid level is associated with cancer, objectType=article, longId=220875, objectId=2a7b2208e510, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a7b2208e510, replyNumber=0, likeNumber=70, createdTime=2022-09-24, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a7b2208e510, moduleTitle=A high serum-free fatty acid level is associated with cancer, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2a7b2208e510)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029972, encodeId=563a20299e2d6, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=Transl Lung Cancer Res: 真实世界研究评估afatinib(阿法替尼)一线治疗晚期EGFR敏感突变的非小细胞肺癌（NSCLC）患者的疗效, objectType=article, longId=295269, objectId=bfe4295269f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfe4295269f7, replyNumber=0, likeNumber=70, createdTime=2022-10-06, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfe4295269f7, moduleTitle=Transl Lung Cancer Res: 真实世界研究评估afatinib(阿法替尼)一线治疗晚期EGFR敏感突变的非小细胞肺癌（NSCLC）患者的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bfe4295269f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029973, encodeId=1dd620299e3d3, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=Target Oncol:吴一龙教授IIIb期研究关注近真实世界中afatinib(阿法替尼)治疗EGFR突变阳性NSCLC患者的疗效, objectType=article, longId=295658, objectId=04a8295658c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04a8295658c9, replyNumber=0, likeNumber=96, createdTime=2022-04-03, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04a8295658c9, moduleTitle=Target Oncol:吴一龙教授IIIb期研究关注近真实世界中afatinib(阿法替尼)治疗EGFR突变阳性NSCLC患者的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=04a8295658c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029967, encodeId=f99b202996ec4, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=Cardiovasc Diabetol：冠状动脉疾病患者的血清Nesfatin-1和DPP4水平及其相关性, objectType=article, longId=215782, objectId=053a215e8212, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=053a215e8212, replyNumber=0, likeNumber=76, createdTime=2021-12-15, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=053a215e8212, moduleTitle=Cardiovasc Diabetol：冠状动脉疾病患者的血清Nesfatin-1和DPP4水平及其相关性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=053a215e8212)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029970, encodeId=9e2b20299e0cc, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=BMC Cancer：真实世界研究比较二线afatinib (阿法替尼)对比化疗治疗一线化疗后进展的晚期肺鳞状细胞癌患者的疗效, objectType=article, longId=291850, objectId=7bef291850d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bef291850d8, replyNumber=0, likeNumber=88, createdTime=2022-03-21, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bef291850d8, moduleTitle=BMC Cancer：真实世界研究比较二线afatinib (阿法替尼)对比化疗治疗一线化疗后进展的晚期肺鳞状细胞癌患者的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7bef291850d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029962, encodeId=f5c820299628b, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=晚期神经内分泌肿瘤的治疗或迎新进展！和记黄埔已向EMA提交Surufatinib的营销授权申请, objectType=article, longId=199177, objectId=3bc11991e7f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3bc11991e7f6, replyNumber=0, likeNumber=65, createdTime=2021-02-28, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3bc11991e7f6, moduleTitle=晚期神经内分泌肿瘤的治疗或迎新进展！和记黄埔已向EMA提交Surufatinib的营销授权申请, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3bc11991e7f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029961, encodeId=90ce2029961a7, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=NEJM：诺华每月注射一次的奥法木单抗ofatumumab在多发性硬化症患者中展现优越疗效, objectType=article, longId=198891, objectId=c95419889159, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c95419889159, replyNumber=0, likeNumber=92, createdTime=2020-11-17, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c95419889159, moduleTitle=NEJM：诺华每月注射一次的奥法木单抗ofatumumab在多发性硬化症患者中展现优越疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c95419889159)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029964, encodeId=87b42029964c2, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=Sci Transl Med：LRRK2通过NFATc2介导突触核病的小胶质细胞神经毒性, objectType=article, longId=202323, objectId=ac0c202323bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac0c202323bd, replyNumber=0, likeNumber=77, createdTime=2021-02-06, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac0c202323bd, moduleTitle=Sci Transl Med：LRRK2通过NFATc2介导突触核病的小胶质细胞神经毒性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ac0c202323bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029960, encodeId=a96b2029960eb, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=和记黄埔的Surufatinib获得FDA授予快速通道指定，用于治疗胰腺和非胰腺神经内分泌肿瘤, objectType=article, longId=192484, objectId=fb0c19248469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb0c19248469, replyNumber=0, likeNumber=75, createdTime=2021-01-15, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb0c19248469, moduleTitle=和记黄埔的Surufatinib获得FDA授予快速通道指定，用于治疗胰腺和非胰腺神经内分泌肿瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fb0c19248469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029966, encodeId=5415202996696, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=Chi-Med公司开始向美国FDA递交Surufatinib治疗晚期神经内分泌肿瘤的申请, objectType=article, longId=204981, objectId=5ad92049818f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ad92049818f, replyNumber=0, likeNumber=0, createdTime=2021-08-25, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ad92049818f, moduleTitle=Chi-Med公司开始向美国FDA递交Surufatinib治疗晚期神经内分泌肿瘤的申请, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5ad92049818f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029965, encodeId=2c57202996520, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=NATURE：Fat1基因缺失增加肿瘤干性和转移潜力, objectType=article, longId=204663, objectId=610f20466310, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=610f20466310, replyNumber=0, likeNumber=76, createdTime=2021-03-29, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=610f20466310, moduleTitle=NATURE：Fat1基因缺失增加肿瘤干性和转移潜力, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=610f20466310)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029959, encodeId=f14b202995937, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=J Gastroenterology：肝FATP5表达与NAFLD患者的肝病炎症进展和肝脂肪流失有关, objectType=article, longId=183874, objectId=ae861838e4ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae861838e4ba, replyNumber=0, likeNumber=75, createdTime=2020-08-07, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae861838e4ba, moduleTitle=J Gastroenterology：肝FATP5表达与NAFLD患者的肝病炎症进展和肝脂肪流失有关, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ae861838e4ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029963, encodeId=2432202996346, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=FDA批准也是**一个多发性硬化症患者自行注射的B细胞疗法Kesimpta（ofatumumab），只需每月注射一次, objectType=article, longId=199785, objectId=1282199e85f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1282199e85f7, replyNumber=0, likeNumber=0, createdTime=2020-11-30, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1282199e85f7, moduleTitle=FDA批准也是**一个多发性硬化症患者自行注射的B细胞疗法Kesimpta（ofatumumab），只需每月注射一次, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1282199e85f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029956, encodeId=e5a2202995665, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=J Appl Oral Sci：visfatin是肥胖与牙周病关系的潜在生物标志物, objectType=article, longId=176655, objectId=6aac1e6655f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6aac1e6655f8, replyNumber=0, likeNumber=64, createdTime=2020-02-20, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6aac1e6655f8, moduleTitle=J Appl Oral Sci：visfatin是肥胖与牙周病关系的潜在生物标志物, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6aac1e6655f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029957, encodeId=f895202995e69, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=J Dent Res：MiR-361-3p/Nfat5信号轴调控成牙骨质细胞分化, objectType=article, longId=177550, objectId=444b1e7550a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=444b1e7550a2, replyNumber=0, likeNumber=72, createdTime=2019-08-24, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=444b1e7550a2, moduleTitle=J Dent Res：MiR-361-3p/Nfat5信号轴调控成牙骨质细胞分化, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=444b1e7550a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029958, encodeId=c4e9202995870, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=Sci Rep：睡眠窒息症男性中nesfatin-1能够影响下丘脑-垂体-性腺轴么？, objectType=article, longId=177950, objectId=0fd21e795078, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fd21e795078, replyNumber=0, likeNumber=89, createdTime=2020-01-13, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fd21e795078, moduleTitle=Sci Rep：睡眠窒息症男性中nesfatin-1能够影响下丘脑-垂体-性腺轴么？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0fd21e795078)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029955, encodeId=a3712029955e1, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=2019年ASCO：Vofatamab治疗晚期尿路上皮细胞癌（膀胱癌）患者的全新数据, objectType=article, longId=160534, objectId=417d16053477, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=417d16053477, replyNumber=0, likeNumber=67, createdTime=2019-10-08, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=417d16053477, moduleTitle=2019年ASCO：Vofatamab治疗晚期尿路上皮细胞癌（膀胱癌）患者的全新数据, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=417d16053477)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2029952, encodeId=d4bb202995238, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, objectTitle=Biochem Biophys Res Commun：白介素-26通过抑制NFATc1-VEGF途径抑制血管生成, objectType=article, longId=135577, objectId=53e21355e769, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53e21355e769, replyNumber=0, likeNumber=89, createdTime=2018-10-28, rootId=0, userName=12498bd5m16暂无昵称, userId=198d2500149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53e21355e769, moduleTitle=Biochem Biophys Res Commun：白介素-26通过抑制NFATc1-VEGF途径抑制血管生成, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=53e21355e769)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

fat

2020-05-29

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

J Clin Oncol：Afatinib（阿法替尼）联合Pembrolizumab（帕博利珠单抗）治疗复发或转移性头颈鳞状细胞癌（HNSCC）患者的疗效：ALPHA研究

2022-06-21

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

Front Oncol：Afatinib（阿法替尼）治疗EGFR突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）的疗效：来自3个IIIb期研究的合并分析

2022-05-08

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

A high serum-free fatty acid level is associated with cancer

2022-09-24

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

Transl Lung Cancer Res: 真实世界研究评估afatinib(阿法替尼)一线治疗晚期EGFR敏感突变的非小细胞肺癌（NSCLC）患者的疗效

2022-10-06

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

Target Oncol:吴一龙教授IIIb期研究关注近真实世界中afatinib(阿法替尼)治疗EGFR突变阳性NSCLC患者的疗效

2022-04-03

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

Cardiovasc Diabetol：冠状动脉疾病患者的血清Nesfatin-1和DPP4水平及其相关性

2021-12-15

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

BMC Cancer：真实世界研究比较二线afatinib (阿法替尼)对比化疗治疗一线化疗后进展的晚期肺鳞状细胞癌患者的疗效

2022-03-21

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

晚期神经内分泌肿瘤的治疗或迎新进展！和记黄埔已向EMA提交Surufatinib的营销授权申请

2021-02-28

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

NEJM：诺华每月注射一次的奥法木单抗ofatumumab在多发性硬化症患者中展现优越疗效

2020-11-17

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

Sci Transl Med：LRRK2通过NFATc2介导突触核病的小胶质细胞神经毒性

2021-02-06

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

和记黄埔的Surufatinib获得FDA授予快速通道指定，用于治疗胰腺和非胰腺神经内分泌肿瘤

2021-01-15

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

Chi-Med公司开始向美国FDA递交Surufatinib治疗晚期神经内分泌肿瘤的申请

2021-08-25

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

NATURE：Fat1基因缺失增加肿瘤干性和转移潜力

2021-03-29

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

J Gastroenterology：肝FATP5表达与NAFLD患者的肝病炎症进展和肝脂肪流失有关

2020-08-07

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

FDA批准也是**一个多发性硬化症患者自行注射的B细胞疗法Kesimpta（ofatumumab），只需每月注射一次

2020-11-30

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

J Appl Oral Sci：visfatin是肥胖与牙周病关系的潜在生物标志物

2020-02-20

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

J Dent Res：MiR-361-3p/Nfat5信号轴调控成牙骨质细胞分化

2019-08-24

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

Sci Rep：睡眠窒息症男性中nesfatin-1能够影响下丘脑-垂体-性腺轴么？

2020-01-13

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

2019年ASCO：Vofatamab治疗晚期尿路上皮细胞癌（膀胱癌）患者的全新数据

2019-10-08

12498bd5m16暂无昵称 (审核中...)

前往app查看评论内容

#fat#

Biochem Biophys Res Commun：白介素-26通过抑制NFATc1-VEGF途径抑制血管生成

2018-10-28

科室
- - 订阅+
  - 更多科室
工具
服务